Edition:
United States

Koninklijke DSM NV (RDSMY.PK)

RDSMY.PK on OTC Markets Group

14.81USD
9 Dec 2016
Change (% chg)

$-0.17 (-1.13%)
Prev Close
$14.98
Open
$14.80
Day's High
$14.86
Day's Low
$14.70
Volume
32,303
Avg. Vol
64,792
52-wk High
$17.88
52-wk Low
$11.33

Latest Key Developments (Source: Significant Developments)

By-health signs strategic cooperation agreement with Royal DSM N.V. China
Friday, 18 Nov 2016 03:00am EST 

By-health <300146.SZ>:Says it signed a strategic cooperation agreement with Royal DSM N.V. China.  Full Article

DSM announces repurchase of shares to cover existing option plans
Friday, 4 Nov 2016 03:00am EDT 

DSM : DSM announces repurchase of shares to cover existing option plans .Based on closing price of DSM share on Euronext Amsterdam on 3 November 2016 this would be equivalent to approximately 93 million euros ($103.25 million).  Full Article

DSM and NHU inaugurate joint venture to produce high performance PPS compounds
Wednesday, 24 Aug 2016 05:45am EDT 

DSM NV : DSM and NHU inaugurate joint venture to produce high performance PPS compounds . DSM has a 60 pct share in DSM NHU engineering plastics (Zhejiang) Co Ltd., with NHU Holding remaining 40 pct . Products, which are branded Xytron PPS, are marketed globally and targeted principally at automotive, electrical and electronics, water management and industrial markets . DSM will be marketing product globally, including China .Joint venture has already captured business in three important applications in both China and Europe.  Full Article

DSM and NHU inaugurate joint venture to produce high performance PPS compounds
Tuesday, 23 Aug 2016 09:44am EDT 

DSM NV : DSM and NHU inaugurate joint venture to produce high performance PPS compounds . DSM has a 60 pct share in DSM NHU engineering plastics (Zhejiang) Co Ltd., with NHU Holding remaining 40 pct . Products, which are branded Xytron PPS, are marketed globally and targeted principally at automotive, electrical and electronics, water management and industrial markets . DSM will be marketing product globally, including China .Joint venture has already captured business in three important applications in both China and Europe.  Full Article

DSM - outlook revised upward
Tuesday, 2 Aug 2016 01:00am EDT 

DSM : Outlook revised upward . Interim dividend of 0.55 euros ($0.6146) per ordinary share . Q2 group net sales up at 1,994 million euros ($2.23 billion), with 5 pct organic growth, and EBITDA up 18 pct . Now expects to deliver full-year 2016 results ahead of medium term targets set out in its strategy 2018 . For 2016 sees increase in ROCE from high double-digit to over 200 basis points . Remain on track with ambitious group-wide improvement and cost saving programs . Q2 EBITDA 328 million euros versus 301 million euros in Reuters Poll . Q2 net sales 1.99 billion euros versus 1.97 billion euros in Reuters Poll .Sees 2016 EBITDA growth for year moving from high-single digit into low to mid teens.  Full Article

DSM succesfully completes secondary offering for Patheon N.V.
Wednesday, 27 Jul 2016 02:00am EDT 

Koninklijke DSM NV : DSM successfully completes secondary offering of shares in Patheon N.V. . Total cash proceeds for DSM are expected to amount to approximately $240 million . DSM now holds approximately 48.7 million ordinary shares, or approximately 34 pct of PATHEON N.V. .DSM expects to realize a book profit of approximately 220 million euros, which will be reported as part of DSM's Q3 2016 results.  Full Article

DSM informs market of final pricing of Patheon IPO
Thursday, 21 Jul 2016 02:06am EDT 

Koninklijke DSM NV : DSM informs market of final pricing of PATHEON N.V. IPO .Initial public offering at $21.00 per ordinary share.  Full Article

DSM to raise $100 Mln by selling part of Patheon stake in IPO
Monday, 11 Jul 2016 08:05am EDT 

DSM to raise $100 Mln by selling part of Patheon stake in IPO : DSM says it will sell 4.9 mln shares in drugs maker Patheon NV in the company's IPO . Patheon shares valued at $19-$22 ahead of IPO on NYSE [nFWN19X0BO] . DSM currently owns 53.5 million shares in Patheon . Patheon is also selling 25.6 million new shares in IPO, will use proceeds to pay down debt . Patheon was created in 2013 in a joint venture between DSM and JLL . In fiscal 2015 Patheon had pre-tax income from continuing operations of $35.2 million on sales of $1.77 billion. Company SEC filing: https://www.sec.gov/Archives/edgar/data/1643848/000156761916002577/0001567619-16-002577-index.htm ((toby.sterling@thomsonreuters.com;)).  Full Article

Koninklijke DSM NV announces amendment to share repurchase program
Friday, 10 Jun 2016 03:00am EDT 

Koninklijke DSM NV : Intends to increase running share repurchase program as announced on 22 Feb 2016 by an additional 300,000 ordinary shares to a total of 3,500,000 ordinary shares . Additional shares repurchased will be used to cover interim stock dividend 2016 . This additional repurchase would be equivalent to approximately 17 million euros .Consequently, total consideration of repurchase program is now estimated to be approximately 180 million euros.  Full Article

Koninklijke DSM NV to distribute FY 2015 dividend of 1.65 euro per share
Friday, 29 Apr 2016 01:01pm EDT 

Koninklijke DSM NV:To distribute FY 2015 dividend of 1.65 euro per share.  Full Article

DSM Q3 core earnings rise, in line with expectations

AMSTERDAM, Nov 3 DSM reported on Thursday third-quarter core earnings and sales rose in line with expectations, as the company benefitted from tight cost control, low commodity prices and higher vitamin prices.